Altimmune, Inc. - SIC # 2830 -

Ticker Exchange SIC # Website Latest Ticker
ALT Nasdaq 2830 altimmune.com

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for Altimmune, Inc.

Why Is Altimmune (ALT) Down 11.3% Since Last Earnings Report? - Jun 12th, 2026 9:30 am
Altimmune Sets Pemvidutide’s Phase 3 MASH Playbook as AUD Data Near - Jun 10th, 2026 7:05 am
Alcohol Use Disorder Market Set to Expand at a 12.1% CAGR During the Forecast Period (2026–2036), Owing to the Emergence of Novel Mechanisms Such as 5-HT3 Pathway, NOP Receptor, mGluR5 NAM, and Other | DelveInsight - Jun 8th, 2026 11:00 am
ALT and the Rise of Dual Agonists Targeting Liver Disease - Jun 8th, 2026 10:09 am
ALT Stock Guide to Pemvidutide's MASH, AUD and ALD Setup - Jun 8th, 2026 10:06 am
Is Altimmune Worth Buying Ahead of 2026 Catalysts? - Jun 8th, 2026 9:53 am
Altimmune Touts Pemvidutide Momentum Ahead of Phase 3 MASH Trial - Jun 4th, 2026 9:08 pm
Pemvidutide Demonstrates Significant Metabolic Improvements in Patients with MASH in New 48‑Week IMPACT Phase 2b Data Presented at EASL 2026 - May 28th, 2026 9:00 am
Altimmune to Participate in Upcoming Investor Conferences - May 27th, 2026 6:30 am
New IMPACT Phase 2b Data Highlight Concurrent Improvements Across Multiple Non-Invasive Markers and qFibrosis-Measured Fibrosis Regression with Pemvidutide in MASH at EASL 2026 - May 27th, 2026 6:00 am
Here's Why You Should Add Altimmune Stock to Your Portfolio Now - May 22nd, 2026 10:14 am
Altimmune's Q1 Loss Narrower Than Expected, Revenues Nil - May 14th, 2026 8:42 am
Altimmune Inc (ALT) Q1 2026 Earnings Call Highlights: Strong Cash Position and Strategic ... - May 13th, 2026 5:01 pm
Altimmune (ALT) Q1 2026 Earnings Transcript - May 13th, 2026 2:59 pm
Altimmune, Inc. Q1 2026 Earnings Call Summary - May 13th, 2026 2:45 pm
Altimmune Q1 Earnings Call Highlights - May 13th, 2026 8:07 am
Altimmune Q1 2026 Earnings Call: Complete Transcript - May 13th, 2026 7:44 am
Altimmune shares climb after first-quarter loss beats expectations (ALT) - May 13th, 2026 7:29 am
Altimmune Announces First Quarter 2026 Financial Results and Business Update - May 13th, 2026 5:30 am
Altimmune to Present Results of Pemvidutide in MASH in an Oral Presentation and Multiple Poster Presentations at EASL Congress 2026 - May 13th, 2026 5:15 am